Nanexa invites to a webcast to present the positive clinical data from NEX-22 once monthly GLP-1, liraglutide project published on last Friday

Referring to the clinical results presented last Friday Nanexa invites to a webcast hosted by Infront Direkt studios at 14:00 pm today, Monday November 25th.

Chairman Dr. Göran Ando, CEO David Westberg and Director Business Development Otto Skolling will present the results as well as an overview of the GLP-1 segment and plans going forward.
“These clinical results put us in a completely new, very exciting situation with a potential to transform the type-2 diabetes and obesity treatment regime to less frequent treatments say David Westberg, CEO Nanexa.”

The comment will be available here.
Viewers will have the opportunity to ask questions via chat.

The comment will also be published on Nanexa's website afterwards.

Datum 2024-11-25, kl 08:00
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!